Comorbidities: Type 2 diabetes: Both are FDA-approved for diabetes (tirzepatide as Mounjaro, semaglutide as Ozempic) Cardiovascular disease: Semaglutide has the cardiovascular outcomes data Sleep apnea: Tirzepatide has shown benefits Injection frequency: Both are once-weekly
Patients should report any semaglutide side effects, such as nausea or digestive issues, for best results
In the pivotal clinical trials that supported FDA approval, adults taking oral semaglutide achieved significantly greater weight loss compared with placebo, averaging around 13.6% weight reduction over 64 weeks in one study
Unlike Ozempic and Wegovy, which primarily focus on GLP-1, Mounjaros unique approach improves insulin secretion while reducing glucagon production
Tesla Cybertruck incident On December 24, 2025, a video from a livestream of Peters hitting a man with a Tesla Cybertruck in Miami-Dade County quickly circulated online